FDA Approves Adcirca (Tadalafil) For PAH; United Therapeutics Ready For U.S. Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
Tadalafil benefit to clinical worsening claim made it into labeling, but not into the indication.
You may also be interested in...
PAH Market Snapshot: Actelion’s Tracleer Faces Stiffer U.S. Competition
United Therapeutics' recently approved pulmonary arterial hypertension drug Adcirca threatens to close in on the vast lead held by Actelion's Tracleer, though surpassing the market pioneer seems nearly impossible. Not to mention, the Swiss-based biotech has an ace up its sleeve with the expansive REVEAL patient registry
PAH Market Snapshot: Actelion’s Tracleer Faces Stiffer U.S. Competition
United Therapeutics' recently approved pulmonary arterial hypertension drug Adcirca threatens to close in on the vast lead held by Actelion's Tracleer, though surpassing the market pioneer seems nearly impossible. Not to mention, the Swiss-based biotech has an ace up its sleeve with the expansive REVEAL patient registry
‘Manual’ Labor May Boost Inhaled Remodulin’s Chances
United Therapeutics hopes plainer instructions will alleviate doctor and patient worry over tricky device-drug combination.